XENE — Xenon Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1582313 ·
British Columbia, Canada
Last close
$38.78
Market Cap
$3.81B
52W High
$72.66
52W Low
$33.38
ADV30
1,373,895
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -120,067,000 | -110,435,000 | 1,199,875,000 | 82,560,000 | 53,493,000 |
| Jun 2026 | 0 | — | -123,155,000 | -110,736,000 | 1,295,772,000 | 119,527,000 | 53,376,000 |
| Mar 2026 | 0 | — | -112,328,000 | -102,302,000 | 1,386,810,000 | 545,867,000 | 48,991,000 |
| Dec 2025 | 0 | — | -109,767,000 | -105,261,000 | 633,163,000 | 199,163,000 | 51,403,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-356,098,000
Investing CF
$-622,631,000
Financing CF
$956,804,000
CapEx
$-1,010,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.70
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,568,853,000
Inventory
—
Receivables
$1,169,000
ST Investments
$868,238,000
EBIT TTM
$-465,317,000
Pretax Income TTM
$-429,509,000
Interest Exp TTM
—
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-462,999,008
Free Cash Flow
$-209,309,120
Enterprise Value
$3,033,777,152
Total Cash
$950,798,016
Total Debt
$6,009,000
Shares Out
98,284,734
Trailing EPS
$-4.69
Book Value
$11.66
ROE
-50.3%
ROA
-32.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,500,000 | -373,070,000 | -345,910,000 | 633,163,000 | 51,403,000 | 581,760,000 | -279,118,000 |
| Dec 2024 | 0 | -279,298,000 | -234,330,000 | 798,139,000 | 43,236,000 | 754,903,000 | -181,389,000 |
| Dec 2023 | 0 | -214,054,000 | -182,393,000 | 964,798,000 | 36,877,000 | 927,921,000 | -151,112,000 |
| Dec 2022 | 9,434,000 | -129,143,000 | -125,373,000 | 754,146,000 | 32,649,000 | 721,497,000 | -101,028,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-409,195,000
OpCashFlow TTM
—
Assets (Latest)
$1,295,772,000
Forward EPS
$-4.63
Max Pain — expiry 2027-01-15
max pain strike: $40.00 · spot: $37.75 · call oi: 6,878 · put oi: 648
Expected Move to 2027-01-15:
±$7.70
(20.40%) —
implied range
$30.05 –
$45.45
· ATM straddle on $37.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | $3.75B | $22.11 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $3.90B | $19.15 | — |
| OGN | Organon & Co. | $3.65B | $13.90 | — |
| ABCL | AbCellera Biologics Inc. | $3.60B | $11.03 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.54B | $27.52 | — |
News headlines (Yahoo Finance, 1h cache)
Xenon Stock Rises 12% in the Past Month on Pipeline Progress
2026-11-17 15:11 · Yahoo
Xenon Pharmaceuticals Inc. Q3 2026 Earnings Call Summary
2026-11-10 13:30 · Yahoo
Xenon Pharmaceuticals Inc (XENE) (Q3 2026) Earnings Call Highlights: $1. ...
2026-11-10 05:11 · Yahoo
Xenon Pharmaceuticals Q3 Earnings Call Highlights
2026-11-10 03:14 · Yahoo
Is Xenon Pharmaceuticals (XENE) Above Fair Value After Phase 2 Progress?
2026-11-10 00:20 · Yahoo
Xenon Pharmaceuticals: Q3 Earnings Snapshot
2026-11-09 21:13 · Yahoo
Xenon to Present at Upcoming Investor Conferences
2026-11-03 21:01 · Yahoo
Xenon to Report Q3 2026 Financial Results on November 9, 2026
2026-11-02 21:01 · Yahoo
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-30 20:01 · Yahoo
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
2026-10-29 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.